Lastly, the combination of the kinase inhibitor sorafenib and chemotherapeutic irinotecan (NEXIRI) has shown promising results as a second or later-line treatment for metastatic colorectal cancer patients with KRAS mutations as well as a treatment option for patients refractory to standard combined chemotherapies [47,48]. The gene discussed is KRAS; the disease is metastatic colorectal cancer.